The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
32
Administered SC
Orange County Research Center
Tustin, California, United States
Orlando Clinical Research Center
Orlando, Florida, United States
New Orleans Center for Clinical Research
New Orleans, Louisiana, United States
Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide
Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC\[0-∞\]) of Tirzepatide.
Time frame: Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose
PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide
PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide.
Time frame: Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.